<code id='B95AE1DC04'></code><style id='B95AE1DC04'></style>
    • <acronym id='B95AE1DC04'></acronym>
      <center id='B95AE1DC04'><center id='B95AE1DC04'><tfoot id='B95AE1DC04'></tfoot></center><abbr id='B95AE1DC04'><dir id='B95AE1DC04'><tfoot id='B95AE1DC04'></tfoot><noframes id='B95AE1DC04'>

    • <optgroup id='B95AE1DC04'><strike id='B95AE1DC04'><sup id='B95AE1DC04'></sup></strike><code id='B95AE1DC04'></code></optgroup>
        1. <b id='B95AE1DC04'><label id='B95AE1DC04'><select id='B95AE1DC04'><dt id='B95AE1DC04'><span id='B95AE1DC04'></span></dt></select></label></b><u id='B95AE1DC04'></u>
          <i id='B95AE1DC04'><strike id='B95AE1DC04'><tt id='B95AE1DC04'><pre id='B95AE1DC04'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:entertainment    Page View:3932

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In